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Background: Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is an evolutionarily conserved gene that is
expressed ubiquitously in human tissues and some tumor tissues. This protein has been found to be associated
with some gynecological cancers; as such, this study aimed to investigate blood HTATIP2/TIP30 levels in patients
with ovarian cancer.
Methods: Twenty-three women with ovarian cancer and 18 patients with various non-cancerous gynecological
complaints (for example, dysfunctional uterine bleeding, fibroids, and urinary incontinence) were included in the
study. The pathological diagnosis of ovarian cancer was adenocarcinoma. HTATIP2/TIP30 concentration in the
patients’ blood samples was determined using ELISA kits.
Results: The HTATIP2/TIP30 level was significantly higher in the cancer group than in the control group (1.84 ± 0.82
versus 0.57 ± 0.13 ng/ml, mean ± SD).
Conclusions: We demonstrated the potential role of HTATIP2/TIP30 in ovarian cancer for the first time, thereby
enlightening future studies targeting HTATIP2/TIP30 in ovarian cancer treatment, diagnosis, and prevention.
Keywords: HTATIP2/TIP30, ovarian cancer, adenocarcinomaBackground
Ovarian cancer is the seventh most common cancer
in women in terms of both incidence and mortality.
The histologic subtypes of ovarian cancer are epitheli-
oid (serous, endometrioid, mucinous, clear cell, and
undifferentiated) and non-epithelioid [1]; the epitheli-
oid subtype accounts for 90% of malignancies [2]. The
onset is often insidious; the symptoms are vague and
may mimic other conditions. This may lead to a delay
in diagnosis, and currently, three-quarters of women
with ovarian cancer are diagnosed when the disease has
spread throughout the abdomen [3,4].
Many factors affect cell growth and related abnormal
tumor growth in ovarian cancer. Epidermal growth fac-
tor receptor (EGFR) is also central to the promotion of
cell growth and has a role in the development of cancer.
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reproduction in any medium, provided the ortarget for novel therapeutic agents. EGFR is a member of
a family of similar molecules called the epidermal growth
factor receptor family. This family also includes human
epidermal growth factor receptor 2 (HER2/neu), Erb3,
and Erb4. HER2/neu overexpression is related to poor
outcome in breast and ovarian cancers [5-8]. A monoclo-
nal antibody, trastuzumab (Herceptin), has been developed
that binds to HER2/neu [5,6]. A 7.3% response rate was
demonstrated, with no significant toxicity, in women with
recurrent ovarian cancer treated with Herceptin [9]. In
addition to these studies demonstrating the role of HER2/
neu in gynecological cancers, Zhang et al. reported that
overexpression of human HIV-1 TAT interactive protein 2
(HTATIP2/TIP30) is associated with HER2/neu status in
breast cancer [10].
HTATIP2/TIP30 is an evolutionarily conserved gene
that is expressed ubiquitously in human tissues and
some tumor tissues. HTATIP2/TIP30 has been shown
to be bound to the transcriptional activation domain of
the human immunodeficiency virus (HIV-1) TAT and to
act as a cofactor to specifically enhanced TAT-activatedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TIP30 in apoptosis and tumor suppression, especially in
controlling the expression of genes involved in apoptosis
and metastasis suppression, indicates that there is a signal
pathway facilitated by HTATIP2/TIP30 and its associated
factors [12-17]. It also interacts with an estrogen receptor
α (ERα)-interacting coactivator CIA and regulates ERα-
mediated c-Myc transcription [18,19]. All of this informa-
tion led us to hypothesize a potential role of HTATIP2/
TIP30 in ovarian cancer.
The aim of our study was to investigate the levels of
HTATIP2/TIP30 in serous ovarian cancers, using the
enzyme-linked immunosorbent assay (ELISA) method,
and to determine whether altered HTATIP2/TIP30 levels
correlate with cancer occurrence.Methods
Patients
Between March 2009 and February 2010, 34 patients
who were suspected of having ovarian cancer and who
visited Ataturk University, Faculty of Medicine, De-
partment of Obstetrics and Gynecology, were evalu-
ated in this study. Before surgery, whole abdominopelvic
magnetic resonance imaging, vaginal ultrasound, and Ca-
125 level testing were performed to determine the presence
of tumors and ascites, according to our routine clinical
approach, and 5 ml of blood were taken. This study was
approved by the Local Human Ethics Committee of the
Ministry of Health.
All of the patients underwent radical cytoreductive
surgery to remove all visible tumors, including hysterec-
tomy, bilateral salpingo-oophorectomy, appendectomy,
infracolic omentectomy, and systemic pelvic and para-
aortic lymphadenectomy. Based on the final pathology
results, those confirmed to have serous ovarian cancer
(n = 23, stages III and IV) were included in the final data
analysis of the study group. After surgical intervention,
the treatment of 11 patients with other cancer types
(mucinous, n = 5; endometrioid, n = 4; clear cell, n = 1;
and Brenner cell, n = 1) was continued with platinum-
based chemotherapy, but they were excluded from the
data analysis.
The 23 patients diagnosed with epithelial serous ovar-
ian cancer (grade I, n = 4; grade II, n = 13; and grade III,
n = 6) were chosen for the study group. During the same
patient selection period, 18 patients with various non-
cancerous gynecological complaints (dysfunctional uter-
ine bleeding, n = 6; fibroids, n = 7; urinary incontinence,
n = 3; and endometrioma, n = 2) who were referred to our
polyclinics were chosen for the control group. The ages of
the subjects in the control group were matched with the
ages of the subjects in the study group. All procedures
were reviewed and approved by the Institutional EthicsCommittee on Human and Animal Research. All subjects
were given an explanation regarding the aim of the study.
Blood sampling
Blood samples were collected from these patients in bio-
chemical tubes and immediately taken to the biochemis-
try laboratory, where they were centrifuged at 4,000 rpm
for 10 minutes at 5°C, and sera was obtained. The sera
were kept at −80°C until the biochemical measurements
for HTATIP2/TIP30 evaluation were conducted.
Biochemical analyses
HTATIP2/TIP30 concentration was determined using a
commercially available ELISA kit (Cusabio Biotech Co.,
Ltd.(Incubator Building 4th floor, Wuhan University
Science Park,No.te-1, Daxueyuan Road, Donghu Hi-Tech
Development Area, Wuhan, Hubei Province 430223, P.R.
China) catalog number: CSB-E14917H ELISA kit). For this
kit, the minimum detectable dose of human HTATIP2 is
typically less than 0.16 ng/ml. The sensitivity of this assay,
or lower limit of detection (LLD), was defined as the lowest
protein concentration that could be differentiated from
zero. Intra-assay precision (precision within an assay) is
CV% < 8%, and inter-assay precision (precision between
assays) is CV% < 10%.
Statistical analyses
The IBM SPSS Statistics 20 (IBM Corporation Software
Group Route 100 Somers, NY 10589)computer program
package was used for statistical calculations. The results
were expressed as mean ± standard deviation (SD). Un-
paired Student’s t-tests were used to analyze the signifi-
cant differences in HTATIP2/TIP30 levels between the
control and ovarian cancer groups.
Results
The women’s age ranges were 42 to 81 years (mean age,
65 ± 24 years) in the study group and 39 to 78 years
(mean age, 59 ± 22 years) in the control group. The
mean parity was 4.2 (1 to 8) in the study group and 4.3
(2 to 8) in the control group. Only a few patients (n = 4)
in the two groups combined were smokers.
As seen in Figure 1, the HTATIP2/TIP30 level was sig-
nificantly higher in the cancer group than in the control
group (1.8363 ± 0.8177 (minimum: 0.82 to maximum:
3.67) versus 0.5659 ± 0.127 (minimum: 0.36 to maximum:
0.79) ng/ml, respectively).
Discussion
Clinical studies regarding the status of HTATIP2/TIP30
expression in cancer patients are limited. The aim of this
study was to demonstrate the involvement of HTATIP2/
TIP30 in advanced epithelial serous ovarian cancer. Tong
et al. [20] showed that downregulation of HTATIP2/TIP30
Figure 1 Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30)
in blood of patients with ovarian cancer and healthy controls.
*P < 0.05, unpaired t-test.
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HTATIP2/TIP30 has also been observed in other cancer
types, including melanoma, colon cancer, breast cancer,
neuroblastoma, and hepatocellular carcinoma [13,14,16].
Several cell culture studies have demonstrated the role of
HTATIP2/TIP30 in a number of tumor cell lines, including
neuroblastoma, breast cancer, glioblastoma, and melan-
oma. In the present study, we found that HTATIP2/TIP30
levels were elevated in the serum samples of patients with
ovarian cancer.
HTATIP2/TIP30 is an evolutionarily conserved gene
that is expressed ubiquitously in human tissues and some
tumor tissues [11]. It is known that there has been very
significant progress in the development of anti-cancer
agents, including tyrosine kinase inhibitors, angiogenesis
inhibitors, and agents that interact with the cell cycle and
cell death (apoptosis). HTATIP2/TIP30 displays a serine-
threonine kinase activity that can phosphorylate the carb-
oxyl terminal domain of RNA polymerase II in a TAT-
dependent manner [12], suggesting that HTATIP2/TIP30
is a potential target for human cancer treatment. In
addition, increasing evidence suggests that receptor tyro-
sine kinase activation participates in the oncogenic pro-
gression from the non-neoplastic mesothelial lining of the
ovaries or the fallopian tube epithelium to epithelial ovar-
ian cancer [21]. In light of these data, we can suggest that
the increase in HTATIP2/TIP30 levels in ovarian cancer
may be related to its intrinsic protein kinase activity.
The discovery of the roles of HTATIP2/TIP30 in apop-
tosis and tumor suppression, especially in controlling
the expression of genes involved in apoptosis and metas-
tasis suppression, indicates that there is a signal pathway
facilitated by HTATIP2/TIP30 and its associated factors
[12-17]. The literature shows that it is believed that the
mechanism of HTATIP2/TIP30’s anti-metastatic proper-
ties is that it inhibits angiogenic properties of tumor cells
and predisposes tumor cells to apoptosis [14,22]. Consist-
ent with the role of HTATIP2/TIP30 in the suppressionof tumor growth and metastasis via transcription mecha-
nisms, studies have revealed that the ectopic expression
of HTATIP2/TIP30 in tumor cell lines upregulates the
expression of pro-apoptotic factors [12] and angiogenic
inhibitors, and downregulates the expression of angiogenic
stimulators [14]. In our study, the increased HTATIP2/
TIP30 levels in the blood samples might be a response to
increased angiogenesis in tumors.
HTATIP2/TIP30 also interacts with an estrogen recep-
tor α-interacting coactivator and regulates ERα-mediated
c-Myc transcription [18,19], suggesting that it has a role
in ovarian cancer. Most of the effects of estrogen are fa-
cilitated by estrogen receptor α, which controls a number
of hormone-responsive genes [23,24] including the c-Myc
gene, which is important for cell proliferation [25-28]. The
finding that HTATIP2/TIP30 acts as a negative regulator
in both unliganded and liganded ERα-mediated c-Myc
expression suggests that HTATIP2/TIP30 might regulate
tumorigenesis and tissue development in ERα-targeted or-
gans [29,30]. In addition, in our study, it was found that
elevated HTATIP2/TIP30 levels might affect ovaries as
ERα-targeted organs.
On the other hand, overexpression of HER2/neu, a
member of the EGFR family, is related to poor outcomes
in breast cancer [5,6] and ovarian cancer [7,8]. Studies are
underway with oral agents that inhibit the tyrosine kinase
activity associated with two oncogenes - EGFR and HER2/
neu. In addition to these studies demonstrating the role of
HER2/neu in gynecological cancers, Zhang et al. reported
that overproduction of HTATIP2/TIP30 is associated with
HER2/neu status in breast cancer [10]. All of these studies
support our findings that HTATIP2/TIP30 has a potential
role in ovarian cancer, and that HER2/neu expression may
be related to increased HTATIP2/TIP30 levels.
Conclusion
In this study, we demonstrated for the first time a poten-
tial role of HTATIP2/TIP30 in ovarian cancer which will
enlighten future studies targeting HTATIP2/TIP30 in
ovarian cancer treatment, diagnosis, and prevention. At
the clinical level, our study is unable to suggest whether
HTATIP2/TIP30 expression is suppressed or enhanced
at the onset of ovarian cancers, when it is confined to
the ovaries. Future clinical and experimental studies are
required to determine the conclusive role of HTATIP2/
TIP30 in ovarian cancer.
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